Caring Brands Inc. Secures Exclusive Global License for Emesyl
Jupiter, Fla., Jan. 5, 2026 (GLOBE NEWSWIRE) — Caring Brands Inc. (Nasdaq: CABR) has announced the signing of an exclusive global license agreement with Itonis Inc. This agreement allows Caring Brands to manufacture, market, and distribute Emesyl, an over-the-counter (OTC) product designed to relieve nausea.
Details of the Exclusive License Agreement
The newly formed partnership grants Caring Brands full rights to commercialize Emesyl and manage all associated manufacturing activities. Under the terms, Caring Brands will take charge of:
- Product manufacturing
- Marketing
- Sales strategy
- Global distribution
Itonis Inc. will support Caring Brands with vital resources, including technical specifications, product formulation data, historical sales information, and intellectual property details to aid in the product’s commercial launch and its ongoing development.
Market Potential for Nausea Treatment
According to QY Research, the global market for nausea treatment and related therapies is anticipated to exceed USD 6.23 billion by 2025. This figure underscores the significant commercial opportunity that the Emesyl license presents for Caring Brands (CABR).
CEO's Vision for the Future
Glynn Wilson, CEO of Caring Brands Inc., emphasized the strategic importance of this agreement, stating, “Securing the exclusive rights to Emesyl marks an important milestone for Caring Brands as we expand our health and wellness portfolio. Emesyl brings a recognized product with real commercial potential, and we look forward to revitalizing and scaling its market presence.”
This collaboration aligns with Caring Brands' long-term strategy for OTC products, and the company is eager to share more about its future plans.
Financial Structure and Next Steps
The license agreement includes a royalty structure based on future net sales and the possibility for Caring Brands to earn equity in Itonis linked to revenue milestones. The company anticipates providing additional updates on product timelines, manufacturing progress, and commercial rollout as developments unfold.
About Caring Brands Inc.
Caring Brands Inc. is committed to a diverse portfolio of unique, patented, and clinically validated products targeting hair and skin growth. The company plans to launch five new products over the next two years while also considering additional in-licensing opportunities.
Management has a solid history of successful strategic acquisitions, rapid product development, and intellectual property advancements. Current revenue is derived from products such as the Hair Enzyme Booster for hair loss and Photocil for psoriasis and vitiligo sold directly in the U.S. and via licensees in India. Other promising product opportunities include CB-101 for eczema and NoStingz, a sunscreen designed to prevent jellyfish stings.
Contact Information
For further inquiries, contact:
Brian S. John
Chief Investment Officer
(561) 896-7616
Forward-Looking Statements
This communication contains forward-looking statements regarding Caring Brands, Inc., including the anticipated timing of studies and their expected results and benefits. These statements can be identified by terminology such as “anticipate,” “estimate,” “expect,” “project,” and other similar expressions.
These forward-looking statements are based on the company’s current plans, objectives, and expectations but involve inherent risks and uncertainties. Actual results may differ materially from those anticipated. Investors are cautioned that forward-looking statements are not guarantees of future performance.